Scientists Uncover the Hidden Mechanism Behind FDA-Approved Alzheimer’s Drug

Scientists present that lecanemab clears amyloid plaques by participating microglia via its Fc fragment, defining the mobile program behind its therapeutic impact Lecanemab, marketed as Leqembi, is a monoclonal antibody remedy for Alzheimer’s illness that reduces the buildup of poisonous amyloid plaques within the mind and slows cognitive decline. Scientists from VIB and KU Leuven […]



Source link